NovoCure Ltd. (NVCR) PT Lowered to $195 at Piper Sandler After Treatment Center Survey
Tweet Send to a Friend
Piper Sandler analyst Jason Bednar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $195.00 (from $235.00) after updating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
